"Persistence has helped us to beat a difficult financing market," Ewert said. Some investors were unable to join this round because of timing difficulties, and discussions with them continue. digitGaps is presenting this report to you to understand company’s key strengths, weaknesses, potential opportunities, and. Xerion was founded in 1998.Įwert added that the company expects to close additional funding within six months. digitGaps report on Xerion Pharmaceuticals AG delivers a detailed in-depth and comprehensive insights of the company, its history, corporate strategy, its businesses and structures, and company operations by examining its performance in local market and global economy. The company is not yet profitable, but Ewert said that the target date for profitability is 2005. Identifizierung und Validierung von Proteinen, die die molekulare Ursache von Krankheiten sind. Over the medium term, Ewert sees the majority of the company's revenue coming from out-licensing opportunities on targets and compounds that are in clinical or preclinical testing. The company will use the funding to develop its own therapeutic pipeline, particularly in antibodies and acute cardiovascular diseases. Xerion plans to bring most of its compounds into Phase II testing. MUNICH, Germany - Xerion Pharmaceuticals AG raised 12.3 million in its third round of financing, which it closed this week. Treatment will have to be after the fact, but able to address the condition," he said. "We want to be able to reach the responsible target with an antibody. It would be surprising if invasiveness were caused by different mechanisms," Ewert added.Īcute cardiovascular diseases, such as thrombosis and stroke, will comprise a second line of inquiry for the company. "Some proteins that are responsible for invasiveness have been found in several different cancer types. "In terms of indications," Ewert said, "we are focusing on the mechanisms underlying cancer metastasis." The company will investigate what makes a cell metastasize and try to find ways to inhibit this tendency. Ewert said those compounds are increasingly finding favor in the market and at major pharmaceutical companies, supplementing their traditional interest in small molecules. Xerion will base its pipeline on antibodies. "All in all, people have been extremely excited about our basic technology and our results so far," and that built investor confidence for moving to the development of therapeutic compounds. "The plan has always been to progress from technology to a therapeutic pipeline," Ewert said. The applications assist in target identification, deactivating selected proteins in a cell and functional site identification, respectively. The company's key products are Xcelerate, XCALIbur and X-plore. "It meets an important market need: to provide solidly characterized targets, with a causative relation between function and disease function." "Our investors have been thrilled about what our technology can provide," Markus Ewert, CEO of Martinsried-based Xerion, told BioWorld International. Existing investors 3i, Burrill & Co., IKB Venture Capital and BioM AG also participated in the round. digitGaps report on Xerion Pharmaceuticals AG delivers a detailed in-depth and comprehensive insights of the company, its history, corporate strategy, its businesses and structures, and company operations by examining its performance in local market and global economy. The round of investment was co-led by Heidelberg Innovation, of Heidelberg, and Nextech Ventures, of Zurich, Switzerland, both of which are investing in Xerion for the first time. If you opt-out your email will still be collected for registration purposes.MUNICH, Germany - Xerion Pharmaceuticals AG raised €12.3 million in its third round of financing, which it closed this week. You have the right to opt-out of sharing your email address with your organization but doing so may negatively affect your organization’s decision to renew their subscription to AdisInsight. The number of times you access AdisInsight, the number of searches you performed, and the number of profiles you viewed will be provided to your organization both in aggregate with other users and individually by your email address. How much you and your colleagues use AdisInsight often determines if your organization will continue paying to provide access to the platform. By accessing or using the AdisInsight platform you agree to the terms of use.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |